Profound Medical (PROF) Non-Current Deffered Revenue (2018 - 2026)
Profound Medical's (PROF) quarterly Non-Current Deffered Revenue came in at $441000.0 in Q1 2026, up 418.82% year-on-year from $85000.0 in Q1 2025, and up 13.66% quarter-over-quarter from $388000.0 in Q4 2025.
Profound Medical (PROF) Non-Current Deffered Revenue (2018 - 2026) Analysis & Trends
Profound Medical's Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $441000.0 for Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue rose 418.82% year-over-year to $441000.0 in Q1 2026; TTM through Mar 2026 was $441000.0, a 418.82% increase from a year earlier, with the FY2025 full-year figure at $388000.0, up 691.84% from the prior year.
- Non-Current Deffered Revenue rose to $441000.0 in Q1 2026 per PROF's latest filing, from $388000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $764000.0 in Q4 2022 and bottomed at $49000.0 in Q4 2024.
- The 5-year median for Non-Current Deffered Revenue is $268000.0 (2025), against an average of $334625.0.
- Across the five-year window, Non-Current Deffered Revenue plunged 93.27% in 2024 and soared 691.84% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $764000.0 in 2022, then declined by 4.71% to $728000.0 in 2023, then plunged by 93.27% to $49000.0 in 2024, then surged by 691.84% to $388000.0 in 2025, then climbed by 13.66% to $441000.0 in 2026.
- Per Business Quant, the three latest PROF Non-Current Deffered Revenue figures stand at $441000.0 (Q1 2026), $388000.0 (Q4 2025), and $148000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.81 Bn | 175.52 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.98 Bn | 126.10 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 68.36 Bn | 66.91 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 47.70 Bn | 44.03 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.67 Bn | 27.55 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 512.79 Mn |
| 10 | Profound Medical | 269.87 Mn | 219.58 Mn | 3.83 Mn | 441,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 441,000.00 |
| Dec 31, 2025 | 388,000.00 |
| Sep 30, 2025 | 148,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 728,000.00 |
| Dec 31, 2022 | 764,000.00 |
| Dec 31, 2021 | 875,000.00 |
| Dec 31, 2020 | 1.08 Mn |
| Dec 31, 2019 | 628,723.64 |
| Jan 1, 2019 | 278,000.00 |
| Dec 31, 2018 | 287,171.24 |